5-n-butoxycarbonylolfuro[2,3-c]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-n-butoxycarbonylolfuro[2,3-c]pyridine
• 英文别名: 5-n-butoxycarbonylfuro[2,3-c]pyridine；butyl furo[2,3-c]pyridine-5-carboxylate
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: VCFCKAMFEDBLEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-甲基-2-糠醛 以 正己烷 、 xylene 为溶剂， 反应 7.5h， 生成 5-n-butoxycarbonylolfuro[2,3-c]pyridine
  参考文献：
  名称：

  Method for producing pyridine derivatives

  摘要：

  一种由通式III表示的吡啶醇衍生物（其中A代表一个二价有机基团，可能含有一到三个氧原子、氮原子和/或硫原子，其中A可以与两个键合的碳原子一起形成一个5、6、7或8元环，该环可以与一个或多个额外的环形成一个紧凑环；R6代表氢原子，-CHR1R2，或烯基基团，芳基基团或芳基烷基基团，可以被取代；R1和R2分别独立地代表氢原子或可以被取代的碳氢基团；R代表氢原子，烷基基团，烯基基团，芳基基团或芳基烷基基团，可以被取代），通过以下方法制备：将由通式I-1表示的吡啶酯衍生物进行反应。

  公开号：

  US06342606B2

文献信息

• Rhodium(III)-Catalyzed Oxidative CH Functionalization of Azomethine Ylides
  作者：Wencui Zhen、Fen Wang、Miao Zhao、Zhengyin Du、Xingwei Li

  DOI：10.1002/anie.201207204

  日期：2012.11.19

  Put it on a ring: A rhodium(III) complex can catalyze the oxidative coupling of azomethine imines with olefins, leading to the synthesis of 1,2‐dihydrophthalazines, olefinated aldehydes, or fused pyridines, depending on the conditions used.

  戴上戒指：铑（III）络合物可以催化偶氮甲亚胺与烯烃的氧化偶联，从而根据所使用的条件导致合成1,2-二氢酞嗪，烯化醛或稠合吡啶。
• Intermediates for producing pyridine derivatives
  申请人：Kuraray Co., Ltd.

  公开号：US06111111A1

  公开（公告）日：2000-08-29

  A pyridine alcohol derivative represented by General Formula III ##STR1## (where A represents a divalent organic group which may contain one to three oxygen atoms, nitrogen atoms and/or sulfur atoms, wherein A may form a 5-, 6-, 7-, or 8-membered ring together with two bonded carbon atoms, where said ring may form a condensed ring with one or more additional rings; R.sup.5 represents a hydrogen atom, --CHR.sup.1 R.sup.2, or an alkenyl group, an aryl group or an aralkyl group which may be substituted; R.sup.1 and R.sup.2 each independently represent a hydrogen atom or a hydrocarbon group which may be substituted; and R.sup.6 represents a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group which may be substituted), is produced by: reacting a pyridine ester derivative represented by General Formula I-1 ##STR2## (where Z.sup.1 represents --COX; X represents an alkoxyl group, an alkenyloxy group, an aryloxy group or an aralkyloxy group which may be substituted; and A is the same as above) with a reducing agent, an alkylating agent, an alkenylating agent, an arylating agent or an aralkylating agent to obtain a pyridine carbonyl derivative represented by General Formula II ##STR3## (where A and R.sup.5 are the same as above); and reacting the resulting pyridine carbonyl derivative with a reducing agent, an alkylating agent, an alkenylating agent, an arylating agent or an aralkylating agent to obtain the pyridine alcohol derivative of the General Formula III.

  通用公式III所代表的吡啶醇衍生物是通过以下步骤制备的：将通用公式I-1所代表的吡啶酯衍生物与还原剂、烷基化剂、烯基化剂、芳基化剂或芳基烷基化剂反应，得到通用公式II所代表的吡啶羰基衍生物；然后将所得的吡啶羰基衍生物与还原剂、烷基化剂、烯基化剂、芳基化剂或芳基烷基化剂反应，得到通用公式III所示的吡啶醇衍生物。
• [EN] CRYSTALLINE FUMARATE SALTS OF 1-AZABICYCLO[2.2.2]OCT SUBSTITUTED FURO[2,3-C]PYRIDINYL CARBOXAMIDE AND COMPOSITIONS AND PREPARATIONS THEREOF<br/>[FR] SELS FUMARATES CRISTALLINS DE FURO[2,3-C]PYRIDINYLE CARBOXAMIDE A SUBSTITUTION 1-AZABICYCLO [2.2.2]OCT ET COMPOSITIONS ET PREPARATIONS CONTENANT LESDITS SELS
  申请人：UPJOHN CO

  公开号：WO2004052894A1

  公开（公告）日：2004-06-24

  The invention provides fumarate salts of N-[1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, compositions, racemic mixtures, or pure enantiomers thereof, and preparation thereof. The fumarate salts are useful to treat diseases or conditions in which α7 nAChR is known to be involved. Formula (I).

  这项发明提供了N-[1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide的富马酸盐、组合物、外消旋混合物或其纯对映体，以及其制备方法。富马酸盐可用于治疗已知与α7 nAChR有关的疾病或病况。公式（I）。
• Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds
  申请人：Corbett W. Jeffrey

  公开号：US20050245504A1

  公开（公告）日：2005-11-03

  The present invention relates to compositions and methods to treat diseases or condition with an α7 nAChR full agonist and an inhibitor of cholinesterase, and or beta secretase and or gamma secretase.

  本发明涉及利用α7 nAChR全激动剂和胆碱酯酶抑制剂，和/或beta秘鲁和/或gamma秘鲁的组合物和方法来治疗疾病或症状。
• Treatment of attention defecit hyperactivity disorder
  申请人：Rogers N. Bruce

  公开号：US20050107425A1

  公开（公告）日：2005-05-19

  The present invention relates to compositions and methods to treat ADHD with an α7 nAChR full agonist and psychostimulants and/or monoamine reuptake inhibitors.

  本发明涉及使用α7 nAChR全激动剂和精神刺激剂和/或单胺再摄取抑制剂的组合物和方法来治疗ADHD。